Dexmedetomidine for sedation of patients in the ICU or PICU review of clinical effectiveness and safety
Sedation of ICU patients is often essential for ICU patients to maximize survival, reduce ICU and hospital stay, and facilitate mechanical ventilation. The standard of care for sedation include benzodiazepine sedatives and propofol. Some drawbacks of the available sedative agents include patients�...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2014, January 2014
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Sedation of ICU patients is often essential for ICU patients to maximize survival, reduce ICU and hospital stay, and facilitate mechanical ventilation. The standard of care for sedation include benzodiazepine sedatives and propofol. Some drawbacks of the available sedative agents include patients' agitation and delirium. To overcome these drawbacks, it has been suggested that dexmedetomidine can be an appropriate alternative to traditional sedatives for maintaining light to moderate sedation. However, the Health Canada approved label for dexmedetomidine provides warnings that the drug is associated with hypotension, clinically significant episodes of bradycardia, and sinus arrest. The objective of the current review is to evaluate the evidence surrounding the use of dexmedetomidine for sedation in intensive-care units |
|---|---|
| Item Description: | Title from PDF caption title. - "CADTH Rapid Response Service.". - "16 January 2014." |
| Physical Description: | 1 PDF file (21 pages) illustrations |